Business
PureTech Begins Ph2a Trial of LYT-300 for anxiety
PureTech Begins Ph2a Trial of LYT-300 for anxiety.
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n 21 June 2023\nPureTech Health plc\n \nPureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders\n \nResults from a validated clinical model of anxiety in healthy volunteers anticipated by the end of 2023\n \nPhase 2a clinical trial of LYT-300 in patients with postpartum depression planned to initiate in second half of 2023\n \nLYT-300 is derived from PureTech's GlyphTM platform, which is designed to enable oral administration of a range of therapeutics\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the initiation of a Phase 2a proof-of-concept clinical trial of LYT-300 (oral allopregnanolone) in healthy volunteers using a validated clinical model of anxiety. LYT-300 is PureTech's wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychiatric disorders, including anxiety disorders and postpartum depression (PPD). LYT-300 is an oral prodrug of allopregnanolone that was developed using PureTech...